Formulation Challenges and Strategies to Develop Pediatric Dosage Forms

The development of pediatric-specific dose forms is particularly difficult due to a variety of factors relating to pediatric population differences from adult populations. The buccal dosage form is considered a good alternative to oral dosage form if the latter cannot be used in pediatric patients....

Full description

Saved in:
Bibliographic Details
Main Authors: Wedad A. Malkawi (Author), Enas AlRafayah (Author), Mohammad AlHazabreh (Author), Salam AbuLaila (Author), Abeer M. Al-Ghananeem (Author)
Format: Book
Published: MDPI AG, 2022-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_37d9dfd5bd0e4f48b5d0af8ca2f7d38b
042 |a dc 
100 1 0 |a Wedad A. Malkawi  |e author 
700 1 0 |a Enas AlRafayah  |e author 
700 1 0 |a Mohammad AlHazabreh  |e author 
700 1 0 |a Salam AbuLaila  |e author 
700 1 0 |a Abeer M. Al-Ghananeem  |e author 
245 0 0 |a Formulation Challenges and Strategies to Develop Pediatric Dosage Forms 
260 |b MDPI AG,   |c 2022-04-01T00:00:00Z. 
500 |a 10.3390/children9040488 
500 |a 2227-9067 
520 |a The development of pediatric-specific dose forms is particularly difficult due to a variety of factors relating to pediatric population differences from adult populations. The buccal dosage form is considered a good alternative to oral dosage form if the latter cannot be used in pediatric patients. Both oral and buccal dosage formulations uphold great application qualities for pediatric patients. This review sheds light on both oral and buccal, as they are the most convenient dosage forms for pediatrics. The use of adult drugs to treat children is a legislation concern, as it may result in incorrect dose, safety, and efficacy. The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) are two key pieces of legislation that encourage and regulate pediatric medication research. Both contribute to a well-balanced approach to emphasizing critical safety and efficacy warnings for the of medications within pediatric populations. These contributions are what enable companies to continue making significant investments in pediatric drug developments. Despite the importance of investigating medicines for children, there is still a demand for pediatric-specific formulations and dosage forms. Many formulations and dosage forms can be designed, among which the buccal drug delivery seems a good modality for pediatric-friendly dosage forms. The main issues associated with these pediatric dosage forms development, particularly clinical and physiological factors, are discussed in this review. In addition, formulation developments and regulatory expectations are highlighted. In turn, suggestions are made to potentially improve future pediatric formulation development. 
546 |a EN 
690 |a pediatrics 
690 |a dosage form 
690 |a formulation development 
690 |a oral 
690 |a buccal 
690 |a regulatory 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Children, Vol 9, Iss 4, p 488 (2022) 
787 0 |n https://www.mdpi.com/2227-9067/9/4/488 
787 0 |n https://doaj.org/toc/2227-9067 
856 4 1 |u https://doaj.org/article/37d9dfd5bd0e4f48b5d0af8ca2f7d38b  |z Connect to this object online.